PUBLIC COMPANY
saveEMERGENT
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Compass to submit psilocybin depression drug for approval imminently after stock wobblesCompass Pathways revealed that an FDA filing for COMP360 will be complete “in the next two weeks,” with an expected drug launch in the first half of next year. The update follows a reported regulat…biospace · 3h ago
- Tiziana touts multiple sclerosis win at lower dose as high dose misses markIn a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after t…biospace · 1d ago
- Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose strugglesTiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose mis…fiercebiotech · 1d ago
- ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancerWhen used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…biospace · 8d ago
- ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 winTakeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival of 10.2 months.fiercebiotech · 11d ago
- Rapport’s epilepsy drug finds surprising success in bipolar trialDespite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.biopharma_dive · 14d ago
- Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trialRapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipol…biospace · 14d ago
- Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 15d ago
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 15d ago
- Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drugA phase 3 trial of Disc Medicine’s bitopertin has hit both co-primary endpoints and all secondary endpoints, positioning the biotech to refile for approval of the once-rejected rare disease drug ca…fiercebiotech · 15d ago
comments(0)
5-min edit window · permanent after that